ETTX - エンタシス・セラピュ―ティクス (Entasis Therapeutics Holdings Inc.) エンタシス・セラピュ―ティクス

 ETTXのチャート


 ETTXの企業情報

symbol ETTx
会社名 Entasis Therapeutics Holdings Inc (エンタシス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   エンタシス・セラピュ―ティクスは米国のバイオ医薬品事業持株会社。子会社を通じ、多剤耐性グラム陰性菌感染症の治療薬の新規発見、開発および商業化に焦点をあて事業を行う。主に多剤耐性アシネトバクタ―感染症、淋病、複雑性尿路感染症などの治療薬の臨床試験を手掛ける。本社所在地はマサチュ―セッツ州ウォルサム。   Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
本社所在地 35 Gatehouse Drive Waltham MA 02451 USA
代表者氏名
代表者役職名
電話番号
設立年月日 42064
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.entasistx.com
nasdaq_url https://www.nasdaq.com/symbol/ettx
adr_tso
EBITDA EBITDA ー
終値(lastsale) 8.31
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 ETTXのテクニカル分析


 ETTXのニュース

   Entasis Therapeutics Hldg: Q1 Earnings Insights  2022/04/27 13:02:13 Benzinga
Entasis Therapeutics Hldg (NASDAQ: ETTX ) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Entasis Therapeutics Hldg missed estimated earnings by 23.08%, … Full story available on Benzinga.com
   Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update  2022/04/27 11:30:00 GlobeNewswire
WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced its first quarter 2022 financial results and provided a business update.
   Recap: Entasis Therapeutics Q4 Earnings  2022/03/03 15:00:01 Benzinga
Entasis Therapeutics Hldg (NASDAQ: ETTX ) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Entasis Therapeutics Hldg beat estimated earnings by 7.41%, … Full story available on Benzinga.com
   Entasis gains on buyout proposal from Innoviva  2022/02/02 14:19:32 Seeking Alpha
Entasis Therapeutics (ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it
   -$0.26 EPS Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This Quarter  2021/12/14 19:20:42 Dakota Financial News
Equities research analysts expect that Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) will post earnings per share of ($0.26) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Entasis Therapeutics earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.26). Entasis Therapeutics posted earnings []
   Recap: Entasis Therapeutics Q4 Earnings  2022/03/03 15:00:01 Benzinga
Entasis Therapeutics Hldg (NASDAQ: ETTX ) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Entasis Therapeutics Hldg beat estimated earnings by 7.41%, … Full story available on Benzinga.com
   Entasis gains on buyout proposal from Innoviva  2022/02/02 14:19:32 Seeking Alpha
Entasis Therapeutics (ETTX) is trading ~15% higher in the pre-market after announcing that its existing investor, Innoviva submitted a non-binding proposal to buy the shares it
   -$0.26 EPS Expected for Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) This Quarter  2021/12/14 19:20:42 Dakota Financial News
Equities research analysts expect that Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) will post earnings per share of ($0.26) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Entasis Therapeutics earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.26). Entasis Therapeutics posted earnings []
   Head to Head Comparison: Entasis Therapeutics (NASDAQ:ETTX) and PyroGenesis Canada (NASDAQ:PYR)  2021/12/03 07:20:42 Dakota Financial News
PyroGenesis Canada (NASDAQ:PYR) and Entasis Therapeutics (NASDAQ:ETTX) are both small-cap industrial products companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk. Profitability This table compares PyroGenesis Canada and Entasis Therapeutics net margins, return on equity []
   Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products  2021/11/17 18:22:33 Seeking Alpha
   Entasis Therapeutics Holdings Inc. (ETTX) CEO Manoussos Perros on Q3 2021 Results - Earnings Call Transcript  2021/11/06 19:50:08 Seeking Alpha
   Entasis Therapeutics EPS beats by $0.02  2021/11/04 11:45:17 Seeking Alpha
   Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update  2021/11/04 11:30:00 Intrado Digital Media
Management to host a conference call on November 4, 2021 at 8:00am ET Management to host a conference call on November 4, 2021 at 8:00am ET
   Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021  2021/10/28 12:00:00 Intrado Digital Media
WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow managements prepared remarks.
   At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting  2021/10/23 14:30:00 Stocks Register
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) concluded the trading at $2.64 on Friday, October 22 with a fall of -5.71% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.80 and 5Y monthly beta was reading 1.72 with its price kept floating in At $2.64 Price, Entasis Therapeutics Holdings Inc. (ETTX) Is Sitting And Waiting Read More »

 関連キーワード  (― 米国株 エンタシス・セラピュ―ティクス ETTX Entasis Therapeutics Holdings Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)